Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Haihe Out-Licenses Japan/Asia Rights for NSCLC Therapy to Taiho Pharma

publication date: Mar 4, 2024

Shanghai Haihe Biopharma out-licensed Japan and Southeast Asia rights for its lead drug, gumarontinib, an approved therapy for non-small cell lung cancer, to Taiho Pharma of Tokyo. In March 2023, gumarontinib was approved in China to treat non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping mutations. Haihe has already applied for Japanese approval of the drug. Taiho will have rights to develop, manufacture and commercialize gumarontinib in its areas. Haihe will receive an upfront payment, and it will be eligible for milestones and royalties based on sales revenues. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here